Summary The detection of disseminated tumor cells in bone marrow is a common phenomenon seen in 30-40% of primary breast cancer patients. Presence of disseminated tumor cells at time of diagnosis as well as persistent tumor cells following therapy are unfavorable prognostic factors. The evaluation of circulating tumor cells in peripheral blood might become a desired alternative to bone marrow biopsy. Circulating tumor cells are detected, depending on stage of the disease and methodology, in 10-80% breast cancer patients. Their prognostic relevance has been demonstrated in adjuvant and metastatic setting. Detection and characterization of circulating tumor cells may become an important biomarker for therapy monitoring and specific targeting of minimal residual disease.
|Translated title of the contribution
|Circulating tumor cells - Already clinical routine or still an object of research? Clinical relevance of circulating tumor cells from peripheral blood using the example of breast carcinoma
|Deutsche Zeitschrift fur Onkologie
|Number of pages
|Published - 2013